4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. (FDMT) from its SEC filings: 2025 revenue $85.2 million (+230195% vs the year before), net margin -164%, free cash flow -$109.6 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $85.2 million |
| Revenue growth | +230195% |
| Net income | -$140.1 million |
| Net margin | -164.4% |
| Free cash flow | -$109.6 million |
| Diluted EPS | $-2.42 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +25107% |
| Cash | $70.4 million |
| Long-term debt | $19.6 million |
| Share count, 1 year | +50% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.